Depomed Inc (NASDAQ:DEPO)

During the Trading Day
21.95 -0.65 / -2.88%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
21.94 -0.0051 / -0.02%
 
Volume: 139.0K
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.3B

Company Description

Depomed, Inc. manufactures and distributes pharmaceutical products. It is a specialty pharmaceutical company focused on the development and commercialization of products to treat pain and other central nervous system conditions. Its core products include Gralise (gabapentin), a once-daily product for the management of postherpetic neuralgia; Zipsor (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain; and Lazanda (fentanyl) nasal spray, a product for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The company has developed and licensed a drug-delivery technology, Acuform. Depomed was founded by John W. Shell on August 7, 1995 and is headquartered in Newark, CA.

Contact Information

Depomed, Inc.
1360 O'Brien Drive
Menlo Park California 94025
P:(650) 462-5900
Investor Relations:

Employees

Shareholders

Other institutional47.66%
Mutual fund holders43.73%
Individual stakeholders11.78%

Top Executives

There are no executives to display.

To view my watchlist

Not a member yet?

Sign up now for a free account